Latest Graft-versus-host disease Stories

PRINCETON, N.J., Jan. 26, 2012 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has recently received approximately $574,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program). This Program enables approved, unprofitable biotechnology businesses to sell their unused Net...

JERUSALEM, Jan. 23, 2012 /PRNewswire/ -- Hadasit Bio-Holdings (TASE: HDST, OTC: HADSY) a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed. Enlivex is developing an innovative drug treatment for autoimmune diseases - diseases in which...

PRINCETON, N.J., Jan. 18, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from long-term stability studies of its proprietary DNI (dominant negative inhibitor) anthrax rPA (recombinant protective antigen) subunit protein vaccine, known as SGX204. SGX204 is a hyperimmunogenic derivative of PA and is being developed as a vaccine to protect against anthrax disease either as a...

Alpha-1-antitrypsin reduced intense inflammation after bone marrow transplant A natural enzyme derived from human blood plasma showed potential in significantly reducing the effects of graft-vs.-host disease, a common and deadly side effect of lifesaving bone marrow transplants. Researchers from the University of Michigan Comprehensive Cancer Center looked at the drug alpha-1-antitrypsin, which is approved by the U.S. Food and Drug Administration for use in people who have a genetic...

Research includes phase III bone marrow transplant study presented as first abstract in the scientific plenary session Researchers from the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, presented results from 31 major studies of blood-related cancers – leukemia, lymphoma and multiple myeloma -- during the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011 in San Diego. Research...

New approach redirects lymphocytes from harming vital organs, without dangers of immunosuppression An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease (GvHD) in blood cancer patients following allogeneic stem cell transplantation (ASCT), according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual...

SAN DIEGO, Dec. 13, 2011 /PRNewswire/ -- Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy. The data are being presented at the 53rd annual American Society of Hematology (ASH) meeting, being held December 10-13, in San Diego,...

Patients who receive a blood stem cell transplant from a donor outside of their family to treat leukemia and other blood diseases are more likely to have graft failure but less likely to experience graft-versus-host disease, a condition caused by the donor cells attacking the recipient's body, if the transplanted blood cells come directly from a donor's bone marrow, rather than from blood stem cells circulating in the donor's bloodstream (PBSCs), according to new research. Although the study...

Hematopoietic cell transplantation (HCT), the transplantation of blood-forming stem cells from the bone marrow, peripheral blood, or umbilical cord blood, is the primary option for treatment for many patients who suffer from various hematologic disorders, including blood cancers, sickle cell disease, bone marrow deficiencies, bleeding disorders, and autoimmune disorders. Research investigating breakthroughs in hematopoietic cell transplantation will be presented today at the 53rd Annual...

Technique expands scarce resources used for cord blood transplant procedure A new method to boost the number of immune cells in umbilical cord blood prior to cord blood transplants for cancer patients appears to lead to a quicker rebuilding of a new immune system in the patient's body than with a conventional cord blood transplant procedure, according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American...